Laboratoire de Biométrie et Biologie Evolutive, Equipe Evaluation et modélisation des effets thérapeutiques, Lyon, France.
Faculty of Philosophy, University of Oxford, Radcliffe Infirmary Quarter, Oxford, UK.
Br J Clin Pharmacol. 2022 Aug;88(8):3638-3656. doi: 10.1111/bcp.15345. Epub 2022 May 2.
The placebo effect and the specific effect are often thought to add up (additive model). Whether additivity holds can dramatically influence the external validity of a trial. This assumption of additivity was tested by Kleijnen et al in 1994 but the data produced since then have not been synthetized. In this review, we aimed to systematically review the literature to determine whether additivity held.
We searched Medline and PsychInfo up to 10 January 2019. Studies using the balanced placebo design (BPD), testing two different strengths of placebos, were included. The presence of interaction was evaluated by comparing each group in the BPD with analysis of variance or covariance.
Thirty studies were included and the overall risk of bias was high: four found evidence of additivity and 16 studies found evidence of interaction (seven had evidence of positive additivity).
Evidence of additivity between placebo and specific features of treatments was rare in included studies. We suggest interventions for placebo-sensitive ailments should be tested in trials designed to take interactions seriously once an exploratory RCTs has proven their efficacy with sufficient internal validity.
安慰剂效应和特效通常被认为是相加的(相加模型)。相加性是否成立会极大地影响试验的外部有效性。Kleijnen 等人于 1994 年检验了这种相加性的假设,但此后的数据尚未综合。在本次综述中,我们旨在系统地回顾文献,以确定相加性是否成立。
我们检索了 Medline 和 PsychInfo 数据库,截至 2019 年 1 月 10 日。纳入了使用平衡安慰剂设计(BPD)、测试两种不同强度安慰剂的研究。通过方差分析或协方差分析比较 BPD 中的每个组,评估是否存在交互作用。
共纳入 30 项研究,整体偏倚风险较高:四项研究发现存在相加性证据,16 项研究发现存在交互作用(7 项研究存在正相加性证据)。
在纳入的研究中,安慰剂和治疗特定特征之间相加的证据很少。我们建议,一旦探索性 RCT 已通过足够的内部有效性证明其疗效,对于安慰剂敏感的疾病,应在设计中认真考虑交互作用的试验中测试干预措施。